The startup develops endovascular stent graft systems that integrate a bio-electric stimulator and a refillable micro-infusion pump to regenerate failing hearts over a 36-month treatment period. This technology provides a minimally invasive circulatory support platform for researchers, addressing the need for effective heart regeneration solutions.
Funding
$36.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with heart failure often experience persistent congestion and impaired heart and kidney function, requiring continuous circulatory support. Current solutions are limited in their ability to provide minimally invasive, long-term hemodynamic support and promote cardiac regeneration.
Solution
Second Heart Assist is developing percutaneous mechanical circulatory support devices designed to improve both heart and kidney function. Their "Whisper" device is a catheter-based pump designed for high-risk percutaneous coronary intervention (PCI), acute decompensated heart failure (ADHF), and cardiogenic shock (CS). The "Freedom" device is a wirelessly powered chronic implant intended for long-term circulatory assistance. These devices aim to provide hemodynamic support with ultra-low hemolysis, potentially improving patient outcomes and quality of life.
Target Audience
The primary target audience includes interventional cardiologists and cardiac surgeons treating patients with heart failure, as well as clinical researchers in the field of mechanical circulatory support.
Features
- "Whisper": Catheter-based pump for short-term circulatory support during high-risk PCI, ADHF and CS.
- "Freedom": Wireless powered chronic implant for long-term circulatory support.
- Designed for high-volume perfusion to kidneys.
- Hemodynamic support with ultra-low hemolysis.